Epidemiology of HIV-associated cryptococcosis in France (1985-2001): Comparison of the pre- and post-HAART eras

AIDS

Volumn 18, Issue 3, 2004, Pages 555-562

  Dromer, Françoise ^a   Mathoulin Pélissier, Simone ^b   Fontanet, Arnaud ^a   Ronin, Olivier ^c   Dupont, Bertrand ^c   Lortholary, Olivier ^a,c  

^a INSTITUT PASTEUR   (France)

^b INSTITUT BERGONIÉ   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

AIDS; Cryptococcosis; Cryptococcus neoformans; Epidemiology; HAART; HIV

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; AFRICA; AGED; BINOMIAL DISTRIBUTION; CRYPTOCOCCOSIS; CRYPTOCOCCUS; FEMALE; FRANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POPULATION; PRIORITY JOURNAL; REGRESSION ANALYSIS; REVIEW; STATISTICAL MODEL; VIRAL CONTAMINATION;

ADOLESCENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; CRYPTOCOCCOSIS; EPIDEMIOLOGIC METHODS; FEMALE; FRANCE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED;

EID: 1642332916     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200402200-00024     Document Type: Review

References (42)

1. Kwon-Chung KJ, Bennett JE. Cryptococcosis. In Medical Mycology. Edited by Kwon-Chung KJ, Bennett JE. Philadelphia: Lea & Febiger; 1992:397-446.
2. Heyderman RS, Gangaidzo IT, Hakim JG, Mielke J, Taziwa A, Musvaire P, et al. Cryptococcal meningitis in human immunodeficiency virus-infected patients in Harare, Zimbabwe. Clin Infect Dis 1998, 26:284-289.
3. Mwaba P, Mwansa J, Chintu C, Pobee J, Scarborough M, Portsmouth S, et al. Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad Med J 2001, 77:769-773.
4. Dupont B, Crewe Brown HH, Westermann K, Martins MD, Rex JH, Lortholary O, et al. Mycoses in AIDS. Med. Mycol 2000, 38(Suppl. 1):259-267.
5. Levitz SM. The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis. Rev Infect Dis 1991, 13: 1163-1169.
6. Hajjeh RA, Brandt ME, Pinner RW. Emergence of cryptococcal disease: epidemiologic perspectives 100 years after its discovery. Epidemiol Rev 1995, 17:303-320.
7. Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS-100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 1995, 8:515-548.
8. Knight FR, Mackenzie DW, Evans BG, Porter K, Barrett NJ, White GC. Increasing incidence of cryptococcosis in the United Kingdom. J Infect 1993, 27:185-191.
9. Dromer F, Mathoulin S, Dupont B, Laporte A, the French Cryptococcosis Study Group. Epidemiology of cryptococcosis in France: 9-year survey (1985-1993). Clin Infect Dis 1996, 23: 82-90.
10. 3. J Infect Dis 1994, 170:1284-1287.
11. Currie BP, Casadevall A. Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. Clin Infect Dis 1994, 19:1029-1033.
12. Sorvillo F, Beall G, Turner PA, Beer VL, Kovacs AA, Kerndt PR. Incidence and factors associated with extrapulmonary cryptococcosis among persons with HIV infection in Los Angeles County. AIDS 1997, 11:673-679.
13. Burckhardt B, Sendi P, Pfluger D, Zimmerli W, Nüesch R, Bucher HC, et al. Rare AIDS-defining diseases in the Swiss HIV cohort study. Eur J Clin Microbiol Infect Dis 1999, 18:399-402.
14. Tansuphasawadikul S, Amornkul PN, Tanchanpong C, Limpakarnjanarat K, Kaewkungwal J, Likanonsakul S, et al. Clinical presentation of hospitalized adult patients with HIV infection and AIDS in Bangkok, Thailand. J Acquir Immune Defic Syndr 1999, 21:326-332.
15. Hakim JG, Gangaidzo IT, Heyderman RS, Mielke J, Mushangi E, Taziwa A, et al. Impact of HIV infection on meningitis in Harare, Zimbabwe: a prospective study of 406 predominantly adult patients. AIDS 2000, 14:1401-1407.
16. Moosa MY, Coovadia YM. Cryptococcal meningitis in Durban, South Africa: a comparison of clinical features, laboratory findings, and outcome for human immunodeficiency virus (HIV)-positive and HIV-negative patients. Clin Infect Dis 1996, 24:131-134.
17. Corbett EL, Churchyard GJ, Charalambos S, Samb B, Moloi V, Clayton TC, et al. Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis 2002, 34:1251-1258.
18. McNeil JI, Kan VL. Decline in the incidence of cryptococcosis among HIV-infected patients [letter]. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 9:206-208.
19. McKinsey DS, Wheat LJ, Cloud GA, Pierce M, Black JR, Bamberger DM, et al. Itraconazole prophylaxis for fungal infection in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. Clin Infect Dis 1999, 28:1049-1056.
20. Hajjeh RA, Conn LA, Stephens DS, Baughman W, Hamill R, Graviss E, et al. Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. J Infect Dis 1999, 179:449-454.
21. Centers for Disease Control and Prevention. Update: AIDS-United States, 2000. MMWR 2002, 51:592-595.
22. Institut de Veille Sanitaire. Surveillance du Sida en France. Situation au 31 mars 2002. Bull Epidémiol Hebd 2002, 27: 133-139.
23. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998, 352:1725-1730.
24. ven Elden LJR, Walenkamp AME, Lipovsky MM, Reiss P, Meis JFGM, de Marie S, et al. Declining number of patients with cryptococcosis in the Netherlands in the era of highly active antiretroviral therapy [letter]. AIDS 2000, 14:2787-2800.
25. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
26. Antinori S, Galimberti L, Magni C, Casella A, Vago L, Mainini F, et al. Cryptococcus neoformans infection in a cohort of Italian AIDS patients: natural history, early prognostic parameters and autopsy findings. Eur J Clin Microbiol Infect Dis 2001, 20: 711-717.
27. Leonard MK, Larsen N, Drechsler H, Blumberg H, Lennox JL, Arellano M, et al. Increased survival of persons with tuberculosis and human immunodeficiency virus infection, 1991-2000. Clin Infect Dis 2002, 34:1002-1007.
28. Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren ML, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000, 30:55-515.
29. Mirza SA, Phelan M, Rimland D, Graviss E, Hamill R, Brandt ME, et al. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis 2003, 36:789-794.
30. Chen S, and the Australasian Society for Infectious Diseases (ASID) Mycoses Interest Group. Cryptococcosis in Australasia and the treatment of cryptococcal and other fungal infections with liposomal amphotericin B. J Antimicrob Chemother 2002, 49(Suppl. S1):57-61.
31. Dromer F, Guého E, Ronin O, Dupont B. Serotyping of Cryptococcus neoformans by using a monoclonal antibody specific for capsular polysaccharide. J Clin Microbiol 1993, 31:359-363.
32. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41:961.
33. Ancelle-Park R. Expanded AIDS case definition. Lancet 1993, 341:441.
34. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: John Wiley Sons; 1989.
35. Neuville S, Dromer F, Morin O, Dupont B, Ronin O, Lortholary O, et al. Primary cutaneous cryptococcosis, a distinct clinical entity. Clin Infect Dis 2003, 36:337-347.
36. Hajjeh R. The changing epidemiology of cryptococcosis: implication for public health. Fifth International Conference on Cryptococcus and cryptococcosis. Adelaide, Australia, March 2002 [abstract S8.1].
37. Chen S, Sorrell T, Nimmo G, Speed B, Currie B, Ellis D, et al. Epidemiology and host-and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Clin Infect Dis 2000, 31:499-508.
38. Dupont B, Drouhet E. Cryptococcal meningitis and fluconazole. Ann Intern Med 1987, 106:778.
39. Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992, 326:83-89.
40. van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, et al. Treatment of cryptococcal meningitis associated with acquired immunodeficiency syndrome. N Engl J Med 1997, 337:15-21.
41. Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000, 30:710-718.
42. Kwon-Chung KJ, Sorrell TC, Dromer F, Fung E, Levitz SM. Cryptococcosis: clinical and biological aspects. Med Mycol 2000, 38(Suppl. 1):205-213.